TriangleNCT01892293 · OUTCOME
Adverse Events Related to Study Treatment
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Up to 12 months
What was measured
Number of Participants with NCI CTCAE Version 4.0 Adverse Events related to study treatment greater than or equal to Grade 3
Analysis population: Participants who received NY-ESO-1ᶜ²⁵⁹T
Groups in this outcome
NY-ESO-1ᶜ²⁵⁹T Cells Administered IV
Participants who received cytoreductive chemotherapy followed by infusion of lentivirus-mediated genetically engineered NY-ESO-1ᶜ²⁵⁹T (Target dose: 1-10 billion cells)
| Group | Source count |
|---|---|
| NY-ESO-1ᶜ²⁵⁹T Cells Administered IV | 2 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| NY-ESO-1ᶜ²⁵⁹T Cells Administered IV | 2 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 2
- denoms
- counts
- group Id
- OG000
- value
- 2
- units
- Participants
- description
- Number of Participants with NCI CTCAE Version 4.0 Adverse Events related to study treatment greater than or equal to Grade 3
- groups
- description
- Participants who received cytoreductive chemotherapy followed by infusion of lentivirus-mediated genetically engineered NY-ESO-1ᶜ²⁵⁹T (Target dose: 1-10 billion cells)
- id
- OG000
- title
- NY-ESO-1ᶜ²⁵⁹T Cells Administered IV
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Participants who received NY-ESO-1ᶜ²⁵⁹T
- reporting Status
- POSTED
- time Frame
- Up to 12 months
- title
- Adverse Events Related to Study Treatment
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice